Organ-Specific Differences in Immunotherapy Response Among Metastatic Cancer Patients
NCT07631611
Brain Diseases, Brain Metastasis
Guangzhou, Guangdong, China
View Trial DetailsNCT Number: NCT02663232
This is a national, multicenter, cross-sectional epidemiological study in adult Spanish participants diagnosed with advanced or metastatic melanoma.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Palma de Mallorca, Balearic Islands, Spain
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Day 1
Presence or absence of mutations in the V600 BRAF oncogene was determined in all eligible participants. Data collection and management of BRAF mutation testing was carried out using the Biomarker point® online platform. The platform was used as an electronic case report form (e-CRF) for collecting information in electronic format via a website. Percentage of participants with BRAF mutation status (mutated BRAF, wild type, not available) were reported.
Time frame: Day 1
Melanoma stages were categorized (according to American Joint Committee on Cancer [AJCC]) as IIIc (advanced stage of melanoma), M1a (metastases to skin, subcutaneous, or distant lymph nodes, normal lactate dehydrogenase (LDH) level, M1b (lung metastases, normal LDH) and M1c (metastases to all other visceral sites and normal LDH or distant metastases to any site combined with an elevated serum LDH level). Of these Stage IIIc was used as the referral category for comparisons.
Time frame: Day 1
Time frame: Day 1
Data were obtained to classify the population with sun exposure as those with low, intermittent or chronic exposure. For the sub-analysis of low, intermittent and chronic exposure, percentages were calculated based on the population with any sun exposure.
Time frame: Day 1
Primary tumor location included limbs (upper and lower extremities), trunk, head/neck, mucosa, uveal, acral, other (other than these specified locations), unknown (exact location unknown), and not available.
Time frame: Day 1
Normal LDH levels range from 140 units per liter (U/L) to 280 U/L.
Time frame: Day 1
Median time from the diagnosis of primary melanoma to advanced disease was determined in years.
Time frame: Day 1
Time frame: Day 1
Time frame: Day 1
Time frame: Day 1
Breslow thickness is defined as the total vertical height of the melanoma, from the very top (called the granular layer) to the area of deepest penetration in the skin. An instrument called an ocular micrometer is used to measure the thickness of the excised (removed) tumor. In general, the higher the Breslow thickness, the worse the prognosis. The classifications were lesser than or equal to (≤) 1.0 millimeters (mm), 1.01 - 2.0 mm, 2.01 - 4.0 mm, greater than (>) 4.0 mm and Unknown.
Time frame: Day 1
Time frame: Day 1
Regression in melanoma is the replacement of tumor tissue with fibrosis, degenerated melanoma cells, lymphocytic proliferation, and telangiectasia formation.
Time frame: Day 1
Vascular invasion is defined as the appearance of cancer cells in the lymphatic and blood streams.
Time frame: Day 1
Time frame: Day 1
Time frame: Day 1
The samples were classified based on the percentage of tumor cells referred to the technique as follows: <60 percent (%), 60-80%, >80% and Unknown.
Time frame: Day 1
Hoffmann-La Roche
Industry
Epidemiological Study of V600 BRAF Mutation in Spanish Patients Diagnosed With Metastatic Melanoma: ABSOLUT-BRAF Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07631611
Brain Diseases, Brain Metastasis
Guangzhou, Guangdong, China
View Trial DetailsNCT02701907
Metastatic Cancers, Neoplasms
Amiens, France
View Trial DetailsNCT02303990
Metastatic Cancers, Neoplasms
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT06678659
Hemic and Lymphatic Diseases, Immune System Diseases
Duarte, California, United States
View Trial Details